Clock Ticks On Pfenex Teriparatide Equivalence Windfall
Key Date In October For Milestone Payment
Executive Summary
Pfenex has less than two months for an “A” designation for therapeutic equivalence for to be granted for its Bonsity (teriparatide) 505(b)(2) product by the US FDA if it wishes to realize maximum value under the companies’ partnership agreement with Alvogen.
You may also be interested in...
Ligand Set For Partnership Opportunities After Completing On Pfenex
Fresh from completing its acquisition of Pfenex, Ligand Pharmaceuticals has laid out the benefits that it expects to gain from the deal.
Ligand Set For Partnership Opportunities After Completing On Pfenex
Fresh from completing its acquisition of Pfenex, Ligand Pharmaceuticals has laid out the benefits that it expects to gain from the deal.
What’s Next? Five Things To Look Out For In October
In October, the period during which Mylan may complete its merger with Upjohn will begin, while the FDA will begin holding monthly stakeholder meetings ahead of the third iteration of the Generic Drug User Fee Amendments program, also known as GDUFA III.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: